Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis

The mouse double minute 2 (MDM2) gene encodes a negative regulator for p53, and the polymorphism SNP285 in the promoter region of MDM2 gene has been implicated in cancer risk, but individual published studies had inconclusive results. Therefore, we performed this meta-analysis to obtain a more preci...

Full description

Bibliographic Details
Main Authors:	Wang, Ping, Wang, Meilin, Li, Sanqiang, Ma, Lingjun, Xi, Shoumin, He, Jing
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116512/

id	pubmed-5116512
recordtype	oai_dc
spelling	pubmed-51165122016-11-27 Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis Wang, Ping Wang, Meilin Li, Sanqiang Ma, Lingjun Xi, Shoumin He, Jing Review Article The mouse double minute 2 (MDM2) gene encodes a negative regulator for p53, and the polymorphism SNP285 in the promoter region of MDM2 gene has been implicated in cancer risk, but individual published studies had inconclusive results. Therefore, we performed this meta-analysis to obtain a more precise estimation between MDM2 SNP285 polymorphism and risk of cancer. A systematic literature search was performed using the PubMed, Embase, and Chinese Biomedical (CBM) databases. Ultimately, 16 published studies comprising 14,573 cases and 9,115 controls were included. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the strength of associations. Overall, MDM2 SNP285 polymorphism was significantly associated with a decreased overall cancer risk with the heterozygous model (OR = 0.89, 95% CI = 0.79–0.99), and reduced ORs were observed with other genetic models (dominant: OR = 0.90, 95% CI = 0.79–1.01 and allele comparison: OR = 0.91, 95% CI = 0.80–1.03) but not reaching statistical significance. Stratification analysis indicated a decreased risk for ovarian cancer, Caucasians, and studies with relatively large sample size. Despite some limitations, this meta-analysis indicated that the MDM2 SNP285 polymorphism was associated with a decreased cancer risk, which warrants further validation in large and well-designed studies. Hindawi Publishing Corporation 2016 2016-11-07 /pmc/articles/PMC5116512/ /pubmed/27890964 http://dx.doi.org/10.1155/2016/4585484 Text en Copyright © 2016 Ping Wang et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Wang, Ping Wang, Meilin Li, Sanqiang Ma, Lingjun Xi, Shoumin He, Jing
spellingShingle	Wang, Ping Wang, Meilin Li, Sanqiang Ma, Lingjun Xi, Shoumin He, Jing Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis
author_facet	Wang, Ping Wang, Meilin Li, Sanqiang Ma, Lingjun Xi, Shoumin He, Jing
author_sort	Wang, Ping
title	Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis
title_short	Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis
title_full	Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis
title_fullStr	Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis
title_full_unstemmed	Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis
title_sort	association of the mdm2 snp285 polymorphism with cancer susceptibility: a meta-analysis
description	The mouse double minute 2 (MDM2) gene encodes a negative regulator for p53, and the polymorphism SNP285 in the promoter region of MDM2 gene has been implicated in cancer risk, but individual published studies had inconclusive results. Therefore, we performed this meta-analysis to obtain a more precise estimation between MDM2 SNP285 polymorphism and risk of cancer. A systematic literature search was performed using the PubMed, Embase, and Chinese Biomedical (CBM) databases. Ultimately, 16 published studies comprising 14,573 cases and 9,115 controls were included. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the strength of associations. Overall, MDM2 SNP285 polymorphism was significantly associated with a decreased overall cancer risk with the heterozygous model (OR = 0.89, 95% CI = 0.79–0.99), and reduced ORs were observed with other genetic models (dominant: OR = 0.90, 95% CI = 0.79–1.01 and allele comparison: OR = 0.91, 95% CI = 0.80–1.03) but not reaching statistical significance. Stratification analysis indicated a decreased risk for ovarian cancer, Caucasians, and studies with relatively large sample size. Despite some limitations, this meta-analysis indicated that the MDM2 SNP285 polymorphism was associated with a decreased cancer risk, which warrants further validation in large and well-designed studies.
publisher	Hindawi Publishing Corporation
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116512/
_version_	1613734267706146816

Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis

Similar Items